Mitogen-activated protein kinase phosphatase 3 (MKP3) is a specific regulator of extracellular signalregulated protein kinase 2 (ERK2). Association of ERK2 with MKP3 results in a powerful increase in MKP3 phosphatase activity. To determine the molecular basis of the specific ERK2 recognition by MKP3 and the ERK2-induced MKP3 activation, we have carried out a systematic mutational and deletion analysis of MKP3. Using activation-based and competition-based assays, we are able to quantitatively evaluate the contributions that residues/regions within MKP3 make to ERK2 binding and ERK2-induced MKP3 activation. Our results show that recognition and activation of MKP3 by ERK2 involves multiple regions of MKP3. Thus, the kinase interaction motif (KIM; residues 61-75) in MKP3 plays a major role (135-fold) for high affinity ERK2 binding. The most important residue in the KIM sequence of MKP3 is Arg 65 , which probably interacts with Asp 319 in ERK2. In addition to KIM, a unique sequence conserved in cytosolic MKPs (residues 161-177 in MKP3) also contributes to ERK2 binding (15-fold). However, these two regions are not essential for ERK2-induced MKP3 activation. A third ERK2 binding site is localized in the C terminus of MKP3 (residues 348 -381). Although deletion of this region or mutation of the putative ERK specific docking sequence 364 FTAP 367 in this region reduces MKP3's affinity for ERK2 by less than 10-fold, this region is absolutely required for ERK2-induced MKP3 activation.
kinase pathway, the last two of which are activated in response to environmental stresses and cytokines that mediate inflammation. MAP kinase activity is tightly regulated by phosphorylation and dephosphorylation. Activation of MAP kinase activity requires dual phosphorylation of both Thr and Tyr residues in the activation loop motif TXY. One mechanism for MAP kinase inactivation involves the action of MAP kinase phosphatases (MKPs). The MKPs are dual specificity phosphatases that are capable of catalyzing the removal of the phosphoryl group from Tyr(P) as well as Thr(P). MKPs are unrelated to the serine/threonine protein phosphatases but belong to the protein tyrosine phosphatase (PTPase) superfamily (4) .
At least nine mammalian MKPs have been identified (5, 6 ). These MKPs share two common structural features: a conserved catalytic domain that contains the PTPase active site signature motif (H/V)CX 5 R(S/T) and an N-terminal domain containing two conserved motifs that are also found in the cell cycle regulator Cdc25 phosphatases. Interestingly, however, each MKP appears to have distinct specificity for its substrate MAP kinase. For example, MKP3 is predominantly localized in the cytoplasm and is highly specific in dephosphorylating and inactivating ERK1/2 (7) (8) (9) (10) . The N-terminal domain of MKP3 can physically associate with ERK1/2 (11), and purified recombinant ERK2 stimulates the phosphatase activity of MKP3 (12) . We sought to understand how these findings contribute to the specificity of MKP3 to ERK2.
To gain insight into the mechanism of ERK2-induced MKP3 activation, we have carried out a detailed kinetic analysis of the MKP3-catalyzed aryl phosphate hydrolysis both in the absence and presence of ERK2 (13) . Our data suggest that, like PTPases, MKP3 can exist either in a general acid loop open or closed conformation. Normally, MKP3 is in the open state in which the active site residues (Cys 293 and Arg 299 ) are misaligned and the general acid (Asp 262 ) is positioned away from the active site (14) . For PTPases, the loop that contains the general acid is brought into the active site as a result of the interactions between the phosphoryl moiety in the substrate and the side chain of the active site Arg, which in turn enables the Arg residue to interact with a hinge residue in the general acid loop (15, 16) . A similar mechanism for loop closure could also occur in MKP3 that allows the repositioning of catalytic groups and the reorienting of the electrostatic environment at the active site. However, unlike PTPases, the rate of this substrate-induced conformational change in MKP3 depends on the nature of the substrates. It appears that with p-nitrophenyl phosphate (pNPP) as a substrate, the interaction between the substrate and MKP3 is not sufficient to allow the attainment of optimal alignment of active site residues with respect to the substrate. Because ERK2 is a physiological substrate of MKP3, it can engage in specific protein-protein interactions with MKP3 and elicit full activation of MKP3 activity by facilitating the repositioning of active site residues and general acid loop closure in MKP3 (13, 17) .
Catalytic activation by MAP kinases has also been observed with other MKPs. In addition, catalytic activation mirrors the substrate selectivity of MKPs; an MKP is only activated by its physiological substrates (5, 6, 12) . These observations suggest a general mechanism by which all members of the MKP family are regulated; the MKPs exist in latent, inactive states, and upon association with specific MAP kinase substrates, the MKPs are activated, leading to selective inactivation of MAP kinases. The molecular basis for the specific MKP activation by MAP kinases is not understood. Our hypothesis is that molecular determinants responsible for the specific MAP kinase-MKP interactions are contained within the interacting proteins themselves. The goal of the current study is to determine the structural features in MKP3 that are important for ERK2 binding as well as ERK2-induced activation. Our results provide a molecular basis by which MKP3 recognizes ERK2 showing how specific interactions between ERK2 and MKP3 modulate the intrinsic catalytic activity and possibly the substrate specificity of MKP3.
EXPERIMENTAL PROCEDURES

DNA Construction of MKP3 and Its Mutants-
The coding sequence for the wild type MKP3 with a C-terminal His 6 tag was produced by PCR using the oligonucleotides GGCCATATGATAGATACGCTCA-GACCCG (NdeI site underlined) and GCCGAATTCTCAGGTGGTGGT-GGTGGTGCGTAGATTGCAGGGAGTC (EcoRI site and His 6 tag underlined) as the 5Ј and 3Ј primers, respectively, using pGEX-4T3-MKP3 (a generous gift from Dr. Marco Muda, University of Michigan) as a template. The PCR product, containing a 5Ј NdeI site and 3Ј EcoRI site and nucleotides encoding MKP3 and a His 6 tag immediately before the stop codon, was subcloned into the pET21a vector (Novagen). MKP3/ C293S was produced by the same procedure using pGEX-4T3-MKP3/ C293S as the PCR template.
To produce C-terminal truncations of MKP3, the oligonucleotide GGCCATATGATAGATACGCTCAGACCCG (NdeI site underlined) was used as the 5Ј primer, and GCCGAATTCTCAGTGGTGGTGGTGG-TGGTGCAGGGTCCTTTCAAAGTC (for MKP3/1-347), GCCGAATTC-TCAGTGGTGGTGGTGGTGGTGAGAGTCCTTGGCACAGC (for MKP3/1-222), and GCCGAATTCTCAGTGGTGGTGGTGGTGGTGCT-GGCTGTTGGACAG (for MKP3/1-203) were used as the 3Ј primers (EcoRI site and His 6 tag underlined). To produce the N-terminal truncations of MKP3 by PCR, the oligonucleotides GCCCATATGGGC-TCGTGCAGCAGCAGCT (for MKP3/152-381), GCCATATGTCCTTCC-CGGTGGAGATTTTG (for MKP3/204 -381) were used as the 5Ј primers (NdeI site underlined), and GCCGAATTCTCAGTGGTGGTGGTGGTG-GTGCGTAGATTGCAGGGAGTC was used as the 3Ј primer (EcoRI site and His 6 tag underlined). To produce MKP3/204 -347, the oligonucleotides GCCATATGTCCTTCCCGGTGGAGATTTTG (NdeI site underlined) and GCCGAATTCTCAGTGGTGGTGGTGGTGGTGCAGGG-TCCTTTCAAAGTC (EcoRI site and His 6 tag underlined) were used as the 5Ј and 3Ј primers, respectively. The coding sequence of these truncated versions of MKP3, containing a 5Ј NdeI site and 3Ј EcoRI site and nucleotides encoding a His 6 tag immediately before the stop codon, were amplified by PCR from pGEX-4T3-MKP3 and were subcloned into the pET21a vector.
To produce MKP3/⌬KIM, in which amino acids 61-75 were deleted from the MKP3 sequence, oligonucleotides GCCCGGGTCTATTCACG-CGCTGCGAGGA (SmaI site underlined), and GCCGAATTCTCAGTG-GTGGTGGTGGTGGTGCGTAGATTGCAGGGAGTC (EcoRI site and His 6 tag underlined) were used to PCR-amplify the MKP3 sequence from residue 76 to 381 from pGEX-4T3-MKP3 and to introduce SamI and EcoRI restriction sites and a C-terminal His 6 tag immediately flanking the stop codon at the C terminus. Then the DNA fragment encoding the sequence of MKP3 from 76 -381 amino acids was ligated into the plasmid pET21a-MKP3-His 6 fragment containing residues 1-60 of MKP3 after digesting with SmaI and EcoRI.
The point mutations of MKP3 were generated by PCRs according to the standard procedure of the QuickChange TM site-directed mutagenesis kit (Stratagene) using the pET21a-MKP3-His 6 plasmid (or pET21a-MKP3/152-381-His 6 , pET21a-MKP3/⌬KIM-His 6 ) as a template. All MKP3 mutants were verified by DNA sequencing.
Protein Expression and Purification-Full-length MKP3 with a Cterminal His 6 tag was expressed and purified using standard procedures of rapid affinity purification with the pET His tag system (Novagen) with minor modifications. Briefly, pET21a-MKP3-His 6 was transformed into BL21(DE3) competent cells by standard procedure. A single colony was selected and grown in LB medium (supplemented with 100 g/ml ampicillin) at 37°C overnight. A 10-ml overnight culture was transferred to 1 liter of LB medium (supplemented with 100 g/ml ampicillin) and allowed to grow at 37°C until the absorbance at 600 nm was between 0.6 and 0.8. Following the addition of isopropylthio-␤-D-galactopyranoside to a final concentration of 1 mM, the culture was incubated at room temperature with shaking for an additional 6 h. The cells were harvested by centrifugation at 5,000 rpm (Sorvall Centrifuge, SS-34 rotor) for 5 min. The cell pellets from 1 liter of culture were resuspended in 30 ml of lysate buffer (20 mM Tris, pH 7.9, 500 mM NaCl, 5 mM imidazole). The cells were lysed by passage through a French pressure cell press at 1,200 p.s.i. twice. Cellular debris was removed by centrifugation at 16,000 rpm for 30 min. A 4-ml 50% slurry of Ni 2ϩ -nitrilotriacetic acid agarose (Qiagen; preequilibrated by lysate buffer) was added to the supernatant. After incubating with gentle agitation at 4°C for 2 h, the matrix was transferred to a column and washed by 20 bed volumes of lysate buffer and 20 bed volumes of 20 mM Tris, pH 7.9, 500 mM NaCl, 20 mM imidazole. The His 6 -tagged protein was eluted by washing the column with 10 bed volumes of 20 mM Tris, pH 7.9, 500 mM NaCl, 100 mM imidazole. The elute was concentrated with a Centriprep-30 filtration unit (Amicon), and the buffer was changed to 25 mM Tris, pH 7.5, 1 mM EDTA, and 2 mM dithiothreitol. The mutants of MKP3 were expressed and purified by the same procedures as the wild-type MKP3. Protein concentration of MKP3 and its mutants was determined using the Bradford dye binding assay (BioRad) diluted according to the manufacturer's recommendations with bovine serum albumin as standard.
pGEX-2T-ERK2 (a generous gift from Dr. Chris Marshall of the Institute of Cancer Research, London) was used to transform BL21(DE3). GST-ERK2 fusion protein was expressed and purified as described (18) . After thrombin cleavage at room temperature for 1 h, ERK2 was eluted from the GST-ERK2-bound glutathione-Sepharose 4B resin. The elute was concentrated with a Centriprep-30 filtration unit (Amicon). Protein concentration of ERK2 was determined using the absorbance at 280 nm using an extinction coefficient of 1.10 ml mg Ϫ1 cm
Ϫ1
. All of the purified proteins were made to 20% glycerol and stored at Ϫ80°C.
Steady-state Kinetics-The phosphatase activity of MKP3 or its mutants was assayed using pNPP as a substrate at 30°C in 50 mM 3,3-dimethylglutarate buffer, pH 7.0, containing 1 mM EDTA with an ionic strength of 0.15 M adjusted by the addition of NaCl. The reaction was initiated by the addition of the enzyme to a reaction mixture (0.2 ml) containing various concentrations of pNPP and quenched after 60 min by the addition of 0.05 ml of 5 N NaOH. The range of substrate concentration used was 0.2-5 K m . The nonenzymatic hydrolysis of the substrate was corrected by measuring the control without the addition of enzyme. After quenching, 0.2 ml of reaction mixture was transferred to a 96-well plate. The amount of product p-nitrophenol was determined from the absorbance at 405 nm detected by a Spectra MAX340 microplate spectrophotometer (Molecular Devices) using a molar extinction coefficient of 18,000 M Ϫ1 cm Ϫ1 . The Michaelis-Menten kinetic parameters were determined from a direct fit of the velocity versus substrate concentration data to Michaelis-Menten equation using the nonlinear regression program KinetAsyst (IntelliKinetics, State College, PA).
Determination of Dissociation Constants-The dissociation constants of MKP3 and its mutants for ERK2 were determined by the activation assay or competitive binding assay at 30°C and pH 7.0, in 50 mM 3,3-dimethylglutarate buffer, containing 1 mM EDTA with an ionic strength of 0.15 M adjusted by the addition of NaCl. For MKP3 and its mutants possessing phosphatase activity, the activation assay was used to determine the binding affinity of MKP3 or its mutants for ERK2. In this assay, the reaction was initiated by the addition of MKP3 in a reaction mixture (0.2 ml) containing 40 mM pNPP and various concentration of ERK2 and quenched after 60 min by the addition of 0.05 ml of 5 N NaOH. The enzymatic and nonenzymatic hydrolysis of pNPP were measured as described above. The dissociation constant K d was calculated by fitting the absorbance at 405 nm versus ERK2 concentration data to Equation 1,
where A is the absorbance at 405 nm of the sample in the presence of ERK2; A 0 is the absorbance at 405 nm in the absence of ERK2; A ϱ is the absorbance at 405 nm when the concentration of ERK2 is infinite; C M is the MKP3 concentration, which is fixed at 0.1 M; C E is the ERK2 concentration during titration; and K d is the dissociation constant for ERK2 binding to MKP3.
For peptides corresponding to the kinase interaction motif (KIM) and the N-terminal fragments of MKP3, which lack phosphatase activity, the competitive binding assay was used to determine the binding affinity for ERK2. In this assay, the reaction was initiated by the addition of 0.1 M MKP3 in a mixture (0.2 ml) containing 20 mM pNPP, 1.2 M ERK2, and various concentration of the KIM peptide or the MKP3 mutant. The reaction was stopped after 60 min by the addition of 0.05 ml of 5 N NaOH. The enzymatic and nonenzymatic hydrolysis of pNPP were measured as described above. The data were fitted to Equation 2 (19) by nonlinear regression analysis,
where the KIM peptide (or MKP3 mutant) and MKP3 are assumed to bind ERK2 competitively, and MKP3 concentration is much smaller than ERK2 concentration. A is the absorbance at 405 nm in the presence of KIM peptide or MKP3 mutant. A 0 is the absorbance at 405 nm in the absence of KIM peptide or MKP3 mutant. A ϱ is the absorbance at 405 nm when the concentration of KIM peptide or MKP3 mutant is
M is the dissociation constant for MKP3 binding to ERK2 with a value of 0.17 M (Table I) , and K d L is the dissociation constant of the peptide (or MKP3 mutant) for ERK2.
Isothermal Titration Calorimetry-All isothermal titration calorimetry experiments were performed using an MCS Isothermal Titration Calorimetry System from Microcal Inc. (Northampton, MA). Experiments at pH 7.0 were conducted at 25°C, in 50 mM 3,3-dimethylglutarate buffer. The ionic strength of the buffer was adjusted to 0.15 M by the addition of NaCl. The ERK2 concentration in the cell of the calorimeter was 90 M, while the KIM peptide in the syringe was 1 mM. High concentration stock solutions were prepared for the peptides with 50 mM 3,3-dimethylglutarate buffer. The stock was diluted to 1 mM with the buffer before titration. The binding data were analyzed using the Origin software (20) . The binding constant K and the enthalpy change ⌬H were used to calculate the free energy change ⌬G and the entropy change ⌬S according to ϪRTlnK ϭ ⌬G ϭ ⌬H Ϫ T⌬S, where R is the gas constant and T is the absolute temperature.
GST Pull-down and Western blot Analysis-The binding interactions between ERK2 and MKP3 or its mutants were examined by GST pull-down and Western blot assay. GST-ERK2 (10 g) in 1 ml of phosphate-buffered saline (140 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 2 mM dithiothreitol, pH 7.3) was immobilized on 20 l of glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) by incubating with gentle agitation at 4°C for 2 h. MKP3 or its mutants (1 g) in 200 l of phosphate-buffered saline were incubated with 20 l of GST-ERK2 bound beads with gentle agitation at 4°C for 2 h. After washing the beads with phosphate-buffered saline buffer, 25 l of 2ϫ SDS sample buffer was added to the beads. The proteins were released by boiling the beads for 5 min. The sample was microcentrifuged at 10,000 rpm for 2 min. The supernatant (10 l) was loaded on 12.5% SDS-polyacrylamide gel. When the electrophoresis was complete, the proteins on the gel were transferred to nitrocellulose membrane using a Trans-Blot SD semidry electrophoretic transfer cell (Bio-Rad) at 150 mA and room temperature for 1 h. After blocking in 15 ml of 5% nonfat dry milk in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6) for 1 h at room temperature, the membrane was incubated with mouse anti-His 6 monoclonal antibody (sc-8036; Santa Cruz Biotechnology, Inc.) with gentle agitation overnight at 4°C. The membrane was washed three times with TBS-T and incubated with goat anti-mouse monoclonal antibody conjugated with horseradish peroxidase (sc-2005; Santa Cruz Biotechnology) in 5% nonfat dry milk in TBS-T with gentle agitation for 1 h at room temperature. The immunocomplexes were detected by chemiluminescence upon incubation with ECL reagents (Amersham Pharmacia Biotech). The membrane was immediately exposed to Kodak BioMax Light Film for 10 s to 2 min to visualize the bound MKP3.
Peptide Synthesis and Characterization-Peptides were synthesized on Rink amide resin (Advanced Chemtech, Louisville, KY) using a standard protocol for 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/N-hydroxybenzotriazole/N-methylmorpholine activation of Fmoc-protected amino acid derivatives (Advanced Chemtech, Louisville, KY). Side chains of Asp, Glu, Ser, and Thr were tert-butyl-protected; Asn, Gln, and His were trityl-protected; Lys was tert-butyloxycarbonyl-protected; and Arg was protected with the 4-methoxy-2,3,6-trimethyl-benzenesulfonyl group.
The coupling reaction was performed in N,N-dimethylformamide for 1.5 h using a 3-fold excess of amino acid. Fmoc removal was performed with 20% piperidine in N,N-dimethylformamide. The N terminus of the peptides was acetylated with 2.5% acetic anhydride and 5% N,N-diisopropylethylamine in N,N-dimethylformamide for 15 min. Final cleavage and side chain deprotection was achieved with 1 M trimethylsilyl bromide, 1 M thioanisole in trifluoroacetic acid with 5% 1,2-ethanedithiol and 1% m-cresol for 15 min under a blanket of nitrogen at 0°C. The resin was removed by filtration, and the remaining trifluoroacetic acid solution was concentrated under nitrogen flow. Dry diethyl ether was added, and the precipitated peptides were collected by centrifugation. The peptides were resuspended, washed twice with ether, dissolved in water, and purified by semipreparative reverse phase HPLC. All peptides were obtained in high yield (Ͼ80%) and in high purity (Ͼ95%, as analyzed by matrix-assisted laser desorption ionization/time of flight mass spectrometry and analytical HPLC).
RESULTS AND DISCUSSION
An Activation-based Assay for the Determination of Binding
Affinity between MKP3 and ERK2-The catalytic activity of MKP3 against pNPP increases when it binds to ERK2 (12) . To determine the stoichiometry of MKP3 binding to ERK2, the dependence of the MKP3-catalyzed pNPP hydrolysis on the ratio of MKP3 to ERK2 was measured, while keeping the total concentration of MKP3 and ERK2 constant. Fig. 1 shows that maximum pNPP hydrolysis is reached at an MKP3 to ERK2 ratio of 1:1, indicating a 1:1 binding stoichiometry between MKP3 and ERK2. We have found that the activation of MKP3 by ERK2 is dose-dependent and saturable (13) . From the concentration dependence of ERK2 on the kinetic parameters k cat /K m (determined at low [pNPP], e.g. 0.1 mM, ϳ0.08 K m ) or k cat (determined at saturating [pNPP], e.g. 40 mM, ϳ31 K m ) for the MKP3-catalyzed reaction, we can determine the dissociation constant (K d ) for ERK2-MKP3 and ERK2-MKP3⅐pNPP complexes, respectively. The K d value of ERK2 for the MKP3⅐pNPP complex determined by this activation-based assay is 0.17 Ϯ 0.04 M at pH 7.0 and 30°C (Fig. 2) , which is similar to the affinity of ERK2 for free MKP3 (data not shown). In addition, we can also determine the maximal level of MKP3 activation upon the addition of ERK2. The k cat increases 9-fold and the K m decreases 8-fold for the MKP3-catalyzed pNPP hydrolysis, resulting in a nearly 70-fold increase in the second order rate constant, k cat /K m (Table I) . Thus, the concentration dependence of activation of MKP3 pNPP phosphatase activity by ERK2 provides a powerful means to quantitatively assess the importance of structural features in MKP3 for ERK2 recognition, both in terms of binding affinity for ERK2 and the ability to be activated by ERK2.
MKP3 Contains a "Kinase Interaction Motif" Responsible for High Affinity ERK2 Binding-Because the N-terminal 1-221 of MKP3 (MKP3/1-221) is able to bind ERK2 (11), we initially focused on this region to identify residues/regions important for ERK2 recognition. Examination of the sequence alignment of all MKPs (Fig. 3) led to the identification of a short sequence motif (residues 61-75 in MKP3) that resembles the KIM found in PTP-SL and STEP (21), PTP-ER (22), HePTP (23) , and possibly in the yeast Ptp3 (24) . The KIM sequences found in these PTPases are critical for ERK2 binding and efficient dephosphorylation of Tyr(P) in the TEY activation loop of ERK2. As this work was in progress, putative KIM sequences characterized by a cluster of two or three positively charged Arg or Lys residues have also been found in MAP kinase activators (e.g. MEKs) and substrates (e.g. RSK1), in addition to the MAP kinase inactivators (e.g. MKP3 and HePTP) (25) (26) (27) (28) . It was suggested that all ERK2-interacting proteins bind ERK2 through a common electrostatic interaction between the positively charged KIM motif and the negatively charged Asp 316 and Asp 319 in ERK2 (27) . This model would predict a simple mutually exclusive competition among various MAP kinase regulators and substrates for MAP kinases. It is not obvious how specificity can be maintained in this model, which is, therefore, not sufficient to explain the available biochemical data.
Although the KIM sequence has been shown, based mostly on GST pull-down and/or immunoprecipitation experiments, to be important for ERK2 binding, the exact contribution of the KIM sequence in MKP3 to ERK2 binding and the ERK2 binding-induced MKP3 activation has not been established. Furthermore, it is not known whether additional regions in MKP3 are also required for specific ERK2 recognition and activation. To further evaluate the importance of the KIM sequence in ERK2 recognition and to identify additional residues/regions in MKP3 that are important for ERK2 binding and activation, we have generated various MKP3 mutants via site-directed, deletion, and truncation mutagenesis (Fig. 4) . The effects of structural alterations in MKP3 on ERK2 binding and activation have been determined using purified MKP3 mutants and ERK2 and the activation-based assay outlined above.
To determine the contribution of the KIM sequence in MKP3 to ERK2 binding and activation, we first deleted the putative KIM sequence (residues 61-75) to generate MKP3/⌬KIM (Fig.  4) . Using the activation-based assay, the K d of MKP3/⌬KIM for ERK2 was determined to be 22.7 M, which is 135-fold higher than that of the wild-type MKP3 (Table I ). This supports the notion that this KIM motif is important for high affinity ERK2 binding. When residues 1-151 or 1-203 were removed from MKP3 (Fig. 4) , the resulting MKP3/152-381 and MKP3/204 -381 displayed K d values for ERK2 that were similar to that of MKP3/⌬KIM (Table I ). These results indicate that the KIM sequence is a major determinant in the N-terminal domain of MKP3 responsible for high affinity ERK2 binding. We then determined the importance of several conserved residues in the KIM sequences of MKPs with preference for ERK2 (Fig. 3,  MKP3 , MKPX, and MKP4). As shown in Table I , when the Arg residues at positions 64 and 74 were replaced by an Ala, the affinity of MKP3/R64A and MKP3/R74A for ERK2 decreased 7.3-and 3.4-fold, respectively. However, when Arg 65 was replaced by an Ala, the affinity of MKP3/R65A for ERK2 decreased 150-fold, which was similar to that of the KIM deletion mutant MKP3/⌬KIM. Finally, substitution of Leu 71 with an Ala reduced the affinity of MKP3/L71A for ERK2 by 2.6-fold. Thus, the most important residue in the KIM sequence for ERK2 binding is Arg 65 . To visualize MKP3 binding to ERK2 directly, we also performed GST pull-down experiments. In these experiments, GST-ERK2 was used to bind His 6 -tagged MKP3 and its mutants. The amount of MKP3 associated with ERK2 was estimated by anti-His 6 antibody (for details, see "Experimental Procedures"). As shown in Fig. 5A , the amount of MKP3 bound to ERK2 in the GST pull-down assay correlates well with the relative affinities of MKP3 for ERK2 determined by the activation assay. However, the GST pull-down assay is not sensitive enough to detect binding interactions with K d values higher than 10 M under our conditions.
It is noteworthy to point out that the KIM or N-terminal deletion MKP3 mutants and the MKP3 mutants with point mutations in the KIM sequence all exhibited basal phosphatase activity similar to that of the wild-type MKP3 in the absence of ERK2 (Table I ). These results indicated that the mutant proteins were folded correctly. Interestingly, these MKP3 mutants with decreased affinity for ERK2 can still be fully activated by ERK2 at saturating ERK2 concentrations (Table I) . This suggests that although the KIM sequence is important for high affinity ERK2 binding by MKP3, it is not essential for the ERK2-induced MKP3 activation.
To study the binding of the KIM sequence to ERK2 further, we synthesized peptides corresponding to the KIM sequences of MKP3, HePTP, and RSK1 (Fig. 6) is slightly lower than that reported previously (13), due to differences in protein concentration determination (Bradford dye binding assay for the GST-ERK2 fusion protein in the early measurements and absorbance at 280 nm for ERK2 derived from thrombin cleavage of the GST fusion protein in the current study).
mination of the binding constant (K), stoichiometry, and the enthalpy change (⌬H) associated with the binding of a ligand to a macromolecule (20) . From these parameters, the Gibbs free energy of binding (⌬G) and the entropy change (⌬S) of binding can also be derived from the expression ⌬G ϭ ϪRTlnK ϭ ⌬H Ϫ T⌬S. From curve fitting of ITC binding isotherms, the stoichiometry for the binding of the peptides to ERK2 was determined to be 1:1 (Table II) . When Arg 64 and Arg 65 were substituted by Ala, the K d for MKP3/KIM/R64A/R65A increased to 1.77 mM, which was 40-fold higher than that of the wild-type MKP3/KIM peptide (Table II) . This supports the notion that the Arg residues in the KIM sequence are important for high affinity binding to ERK2. (30) . The same mutation in mammalian ERK2 (ERK2/D319N) appears to be resistant to inactivation by MKPs in transfected cells (31, 32) . Previous studies indicate that ERK2/D319N displays reduced affinity for MKP3 and is unable to activate the MKP3 phosphatase activity (12, 27) . However, using the quantitative activation-based assay, we were able to determine the K d of ERK2/D319N for MKP3 (14.8 Ϯ 1.2 M), which is 87-fold higher than that of the wildtype ERK2. More importantly, we found that ERK2/D319N can activate MKP3 to the same level induced by the wild-type ERK2 when a saturating amount of ERK2/D319N is added to the reaction. Thus, like Arg 65 in MKP3, Asp 319 in ERK2 plays a major role in ERK2 binding to MKP3, but it is not essential for ERK2-induced MKP3 activation.
A Competition-based Assay for the Determination of Binding Affinity of Fragments/Domains of MKP3 Involved in ERK2
Recognition-The activation-based procedure described above is ideal for the quantitative measurement of the binding affinity of MKP3 and its catalytically active variants with ERK2. However, it is not suitable for the analysis of MKP3 fragments/ domains that lack phosphatase activity. For example, although the N-terminal noncatalytic domain (amino acids 1-221) of MKP3 binds ERK2 (11), it is not known how tight this association is as compared with the wild-type MKP3. We have developed a competition-based assay to quantitatively determine the binding affinity of catalytically inactive MKP3s for ERK2. The rationale for this approach is that peptides/fragments in MKP3 required for the ERK2-induced MKP3 activation should function as inhibitors/competitors of the ERK2-induced MKP3 activation. Thus, peptide ligands that compete with MKP3 for ERK2 binding should exhibit a dose-dependent inhibition of the ERK2-induced MKP3 activation (Fig. 7) . Nonlinear regression curve fitting of the inhibition data by MKP3/1-222 and MKP3/1-203 to Equation 2 yields a K d value of 2.60 Ϯ 0.28 and 7.03 Ϯ 0.70 M, respectively, for ERK2 binding (Table III) mined by the competition-based assay (Fig. 5B) . Similarly, the K d value of the catalytically inactive active site Cys 293 to Ser mutant MKP3 (MKP3/C293S) for ERK2 was determined to be 0.13 Ϯ 0.01 M, which is similar to that of wild-type MKP3 for ERK2. As a control, the catalytically inactive Cdc25A/C430S, which contains two CH2 domains flanking its active site, is unable to inhibit the ERK2-induced MKP3 activation at 100 M concentration.
Using the competitive binding assay described above, we have also determined the binding affinities of the KIM peptides for ERK2. As shown in Table III , the K d values for MKP3/KIM, MKP3/KIM/L71A, and HePTP/KIM determined by the competitive assay are similar to those obtained from the ITC experiments (Table II) . Surprisingly, the binding of the KIM peptides with ERK2 does not completely abolish the activation of MKP3 by ERK2 even at saturating concentrations of the KIM peptides ( Fig. 7 and Table III ). This is in contrast to MKP3/1-203, MKP3/1-222, and MKP3/C293S, which completely suppress the ERK2-induced MKP3 activation (Fig. 7) . No obvious inhibition of the ERK2-induced MKP3 activation by MKP3/KIM/ R64A/R65A and RSK1/KIM peptides is observed. These data suggest that the KIM sequence in MKP3 is not the sole determinant for high affinity ERK2 binding.
Ionic Strength Dependence of Binding between MKP3 and ERK2-It appears that the major driving force for the recognition of ERK2 by MKP3 may involve electrostatic interactions between Arg 65 of MKP3 and Asp 319 of ERK2 (Refs. 12 and 27 and this study). If this charge-charge interaction is the only determinant for MKP3 binding to ERK2, then binding affinity of ERK2 with MKP3 should decrease when solution ionic strength is increased. This is in part due to the ability of ions to "screen" electrostatic interactions. By contrast, higher salt concentrations tend to favor hydrophobic interactions. Using the assays described above, we have examined the dependence of binding of MKP3 with ERK2 on salt concentration. We found that as the ionic strength of the solution increased from 0.03 to 0.5 M, the affinities of MKP3, MKP3/C293S, and MKP3/1-222 for ERK2 did not change (Table IV) . This suggests that both electrostatic and hydrophobic interactions are involved in MKP3 (or MKP3/1-222) binding to ERK2. Interestingly, the K d value of HePTP/KIM for ERK2 increased 3-fold, indicating the importance of electrostatic interactions (Table IV) . As expected, when the KIM sequence or the Arg residues are removed from MKP3, the K d values of MKP3/⌬KIM and MKP3/R64A/R65A for ERK2 decrease 3-fold, suggesting the importance of hydrophobic interactions (Table IV) . Collectively, these results suggest that the association between ERK2 and MKP3 is not a simple charge-charge interaction. Besides the KIM sequence, other regions in the MKP3 sequence must also be involved in ERK2 binding through hydrophobic interactions.
The KIM Sequence in MKP3 Is Not the Only Region Involved in ERK2 Recognition-Based on our quantitative analyses, we believe that specific ERK2 recognition by MKP3 involves multiple regions of MKP3. First, we have shown that deletion or mutation of the KIM sequence in MKP3 can lead to dramatic decrease in affinity of MKP3 for ERK2. However, it is important to note that these MKP3 mutants can still be fully activated by ERK2 at saturating ERK2 concentrations (Table I) . Second, we have demonstrated that KIM peptides from HePTP, RSK1, and MKP3 are able to bind to ERK2. However, unlike a Because of the weak affinity between the peptide MKP3/KIM/R64A/R65A and ERK2, it is difficult to obtain a reliable fit of the data to the binding isotherm. Therefore, the K d and ⌬H values were determined by setting the n value to 1 for curve fitting analysis. No inhibition up to 100 M MKP3/C293S, the KIM peptides were only able to suppress the ERK2-induced MKP3 activation by 30% at saturating peptide concentrations (Fig. 7) . Third, we found that the affinities of the KIM peptides for ERK2 decreased as the salt concentration was raised, whereas the affinities of MKP3/⌬KIM and MKP3/ R64A/R65A for ERK2 increased as the salt concentration was raised. By contrast, high salt concentrations have no effect on the K d values of MKP3 and MKP3/C293S for ERK2, suggesting that both electrostatic and hydrophobic interactions are involved. Finally, the N-terminal domain (residues 1-221) is known to be able to bind ERK2. We have determined that the K d value of MKP3/1-222 for ERK2 is 2.6 M (Fig. 7) , which is 15-fold lower than that of the wild-type MKP3. This indicates that the C-terminal domain of MKP3 also contributes to ERK2 binding. Collectively, these results suggest that the KIM motif is not the only determinant for ERK2 binding, and specific recognition and activation by ERK2 involves multiple regions of MKP3.
The C-terminal Domain of MKP3 Is Important for MKP3 Activation by ERK2-The fact that MKP3/1-222 binds ERK2 with a 15-fold lower affinity than that of the wild-type MKP3 reveals the importance of the C-terminal domain of MKP3 in ERK2 recognition. An examination of the amino acid sequence alignment of the MKPs (Fig. 3) indicated the presence of a putative FXFP motif in the C terminus of MKP3 ( 364 FTAP 367 ). The FXFP sequence has been identified as a conserved docking site that mediates ERK binding to its substrates in multiple protein families (33) . Interestingly, similar FXFP sequences can also be found in MKPs (MKP3, MKP4, MKPX, MKP1, and MKP2) that are capable of inactivating ERK (Fig. 3) . To establish the importance of the sequence 364 FTAP 367 in ERK2 binding and MKP3 activation, we deleted the last 34 residues from MKP3, yielding MKP3/1-347. Using the activation-based assay, we determined that MKP3/1-347 binds ERK2 with 7-fold lower affinity than the wild-type MKP3. Strikingly, MKP3/1-347 could only be activated by ERK2 to 15% of the wild-type MKP3 k cat /K m value at saturating ERK2 concentrations ( Table  V) . Note that elimination of the C-terminal 34 residues in MKP3 does not affect its ability to hydrolyze pNPP in the absence of ERK2 (Table V) . This is very different from mutations in the N-terminal MKP3 domain (point mutations or deletions/truncations). Thus, the C terminus of MKP3 is important for the specific activation by ERK2.
We converted the four residues of the 364 FTAP 367 sequence to AAAA to determine the contribution of 364 FTAP 367 to ERK2 binding and MKP3 activation. The resulting mutant MKP3/A4 displays kinetic parameters similar to those of the wild-type MKP3 in the absence of ERK2. However, MKP3/A4 exhibits a 4-fold lower affinity toward ERK2 and can only be activated to 32% of the wild-type MKP3 k cat /K m value by ERK2 (Table V) . The relative affinities of MKP3/1-347 and MKP3/A4 estimated by the GST pull-down experiments are consistent with the K d values determined by the activation-based assay (Fig. 5B) . Moreover, conversion of 364 FTAP 367 to AAAA in MKP3/⌬KIM, MKP3/R64A/R65A, and MKP3/152-381 further reduces the affinities of these proteins to ERK2 and drastically impairs their ability to be activated by ERK2 (Table V) . These results indicate that the 364 FTAP 367 sequence in MKP3 plays an important role for both ERK2 binding and binding-induced activation.
We also prepared MKP3/204 -347, which corresponds to the catalytic domain of MKP3. This is the same construct used in an early x-ray crystal structure study (14) . In the absence of ERK2, MKP3/204 -347 displays similar activity as the wildtype MKP3. However, no appreciable activation of MKP3/204 -347 is observed in the presence of ERK2 (Table V) . Because MKP3/152-381/A4 has higher affinity for ERK2 than MKP3/ 204 -347, and MKP3/152-381 has higher affinity for ERK2 than MKP3/204 -381, it is possible that residues between 153 and 204 may also participate in ERK2 binding.
Residues 161-177 of MKP3 Are Also Involved in ERK2 Recognition-When the sequence alignment of the MKPs was further examined, we discovered that there is a sequence just after the second CH2 motif in MKP3, residues 161-177, which is also conserved in MKPX and MKP4, but not in other MKPs (Fig. 3) . MKP3, MKPX, and MKP4 are cytosol-localized MKPs. In fact, residues 162-170 have previously been suggested to serve as a nuclear export signal that may be responsible for the cytoplasmic localization of MKP3 (10) Table V) . Note that the relative affinities of these MKP3 mutants determined by the GST pull-down experiments approximate those measured by the activation-based assays (Fig. 5C ). Like the KIM deletion mutants, MKP3/L167A, MKP3/L170A, and MKP3/L167A/L170A can still be activated to the wild-type MKP3 level by ERK2 (Table V) . These data indicate that Leu 167 and Leu 170 play a role in ERK2 binding but they are not required for the ERK2-induced MKP3 activation.
Summary-Although the upstream signaling processes that activate MAP kinases have been extensively characterized, considerably less is known about how MAP kinase activity is down-regulated. MKP3 is predominantly localized in the cytoplasm, forms a physical complex with ERK2, and is highly specific for ERK2 inactivation. Furthermore, purified recombinant ERK2 stimulates the phosphatase activity of MKP3 toward pNPP. To gain further insights into the molecular mechanism of the specific ERK2 recognition by MKP3 and the ERK2-induced MKP3 activation, we have carried out a systematic mutation and deletion analysis of MKP3. The mutant MKP3s have been quantitatively analyzed for their ability to bind ERK2 and for their propensity to be activated by ERK2, using an activation-based and a competition-based assay. Our results show that the recognition of and activation by ERK2 involves multiple regions of MKP3.
We have shown that the KIM sequence (residues 61-75) in MKP3 is important for high affinity ERK2 binding. Deletion of the KIM sequence from MKP3 results in a 135-fold reduction in ERK2 binding affinity. We have identified a unique sequence conserved in cytosolic MKPs (residues 161-177 in MKP3) that also contributes to ERK2 binding (15-fold). Although both the KIM sequence and residues 161-177 are involved in ERK2 binding, these two regions are not essential for ERK2-induced MKP3 activation. ERK2-induced MKP3 activation requires a third ERK2 binding site localized in the C terminus of MKP3 (residues 348 -381). We have determined that although deletion of this region or mutation of the putative ERK-specific docking sequence 364 FTAP 367 in this region reduces MKP3's affinity for ERK2 by less than 10-fold, this region is absolutely required for ERK2-induced MKP3 activation. Collectively, our data indicate that the KIM sequence and residues 161-177 in MKP3 are important for high affinity ERK2 binding, while the C terminus of MKP3 including the sequence 364 FTAP 367 is primarily responsible for ERK2-induced MKP3 activation.
Our study documents that specific ERK2 recognition by MKP3 involves multiple regions of MKP3. Data from mutagenesis studies of various protein-protein interfaces suggest that the binding energy is not evenly distributed over the entire protein interaction surface but rather concentrated in energetic "hot spots," in which only a small subset of amino acids accounts for most of the change in binding free energy (35, 36 (37) . The energetically less important residues probably surround the hot spot interactions and serve to occlude bulk solvent from the hot spot. Together, the basic and large hydrophobic amino acids in the KIM sequence, residues 161-177, and the C terminus of MKP3 cooperatively promote specific association of MKP3 with ERK2 through a combination of hot spot electrostatic interactions and apolar surrounding hydrophobic interactions.
